INVEST endorses Verapamil in hypertensives with CAD and highlights diabetes prevention.
D001262:Atenolol / Q000008:administration & dosage* / Q000009:adverse effects; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis* / Q000401:mortality*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014700:Verapamil / Q000008:administration & dosage* / Q000009:adverse effects
D001262:Atenolol; D014700:Verapamil